The Federal Trade Commission (FTC) is warning drug companies against improper patent filings, saying that they could potentially face legal action for doing so. The FTC issued a statement Thursday saying that brand drug manufacturers could be harming competition in the generic market by improperly listing patents in the Food and Drug Administration’s “Orange Book” — a list of certain patents on products that a brand name says would cover its product. “Brand drug manufacturers are responsible for ensuring their patents are properly listed. Yet certain manufacturers have submitted patents for listing in the Orange Book that claim neither the reference listed drug nor a method of using
Hence then, the article about ftc warns drugmakers against improper patent filings was published today ( ) and is available onThe Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( FTC warns drugmakers against improper patent filings )